



Updated Data for Epacadostat, Incyte's Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016

July 19, 2016

Data from the Phase 1 portion of the ECHO-202 study evaluating epacadostat in combination with Keytruda® (pembrolizumab) to be highlighted as a poster discussion

WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 19, 2016-- Incyte Corporation (Nasdaq:INCY) announces that updated data from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for a poster discussion at the European Society for Medical Oncology (ESMO) Annual Congress 2016, taking place in Copenhagen, Denmark from October 7-11, 2016. The ECHO-202 study (NCT02178722) is evaluating the safety and efficacy of epacadostat, Incyte's selective IDO1 inhibitor, in combination with Keytruda® (pembrolizumab)*, Merck's anti-PD-1 therapy.

Poster details:

Epacadostat Plus Pembrolizumab in Patients With Advanced Melanoma and Select Solid Tumors: Updated Phase 1 Results From ECHO-202/KEYNOTE-037 (Abstract #1110PD)

- Monday, 10 October 2016 from 11:00-12:00 CET

Full session details and data presentation listings for ESMO 2016 can be found at <http://esmo.org/Conferences/ESMO-2016-Congress/Programme>.

About Epacadostat (INCB024360)

Indoleamine 2,3-dioxygenase 1 (IDO1) is a key immunosuppressive enzyme that modulates the anti-tumor immune response by promoting regulatory T cell generation and blocking effector T cell activation, thereby facilitating tumor growth by allowing cancer cells to avoid immune surveillance. Epacadostat is a first-in-class, highly potent and selective oral inhibitor of the IDO1 enzyme that reverses tumor-associated immune suppression and restores effective anti-tumor immune responses. In single-arm studies, the combination of epacadostat and immune checkpoint inhibitors has shown proof-of-concept in patients with unresectable or metastatic melanoma. In these studies, epacadostat combined with the CTLA-4 inhibitor ipilimumab or the PD-1 inhibitor pembrolizumab improved response rates compared with studies of the immune checkpoint inhibitors alone. A Phase 3 study, ECHO-301, evaluating the combination of epacadostat with the anti-PD-1 antibody pembrolizumab for the first-line treatment of patients with advanced or metastatic melanoma has recently been initiated. Ongoing Phase 1 and Phase 2 studies are investigating epacadostat in combination with PD-1 and PD-L1 inhibitors in a variety of other cancer histologies.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Follow @Incyte on Twitter at <https://twitter.com/Incyte>.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data regarding the Company's ECHO-202 study, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company's development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended March 31, 2016. Incyte disclaims any intent or obligation to update these forward-looking statements.

* KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160719005754/en/>

Source: Incyte Corporation

Incyte Corporation

Media:

Catalina Loveman, +1 302-498-6171

cloveman@incyte.com

or

Investors:

Michael Booth, DPhil, +1 302-498-5914

